Bibliography
- PAWANKAR R, YAMAGISHI S, TAKIZAWA R et al.: Mast cell-IgE-and mast cell-structural cell interactions in allergic airway disease. Carr: Drug Targets Inflanon. Allergy (2003) 2(4):303–312.
- MARSHALL IS, McCURDY JD, OLYNYCH T: Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int. Arch. Allergy brilnunol (2003) 132(2):87–97.
- NORRIS AA, HOLGATE ST: Cromolynsodium and nedocromil sodium. In: Allergy: Principles and Practice (5th Edition). ER Middleton et al. (Eds), Mosby-Year Book, MO, USA (1998):661–667
- PERSIANI S, D'AMATO M, MAKOVEC F et al.: Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. Biophann. Drug. Dispos. (2001) 22(2):73–81.
- GUYER B, SHIMAMOTO S, BRADHURST A et al.: The effect of novel inhibitor of mast cell activation on 740Expert Op/n. lnvestig. Drugs (2004) 13(7) mediators, symptoms and nasal patency in allergic rhinitis. I A//. Clin. Immunol. (2004) 113(2):S28.
- HE S, ASLAM A, GACA MD et al: Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release. Pharmacol Exp. The]: (2004) 309(1):119–126.
- KRISHNA MT, CHAUHAN A, LITTLE L et at Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. I Allergy Clin. Immunol. (2001) 107:1039–1045.
- ERIN EM, ZACHARASIEWICZ AS, HIGGINS LA et al.: A reversible inhibitor of mast cell 3-tryptase and trypsin (RWJ-58643) causes inhibition of symptoms, eosinophils and IL-5 following nasal challenge with timothy grass pollen in patients with allergic rhinitis. Am. I Resp. Grit. Care Med. (2004) 169:A859.
- HIRAI H, TANAKA K, YOSHIE 0 et ai: Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. (2001) 193:255–261.
- ARIMURA A, YASUI K, KISHINO J et al.: Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751.1 Pharmacol Exp. Thec (2001) 298(2):411–419.
- LING P, NGO K, NGUYEN S et al: Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br. Pharmacol (2004) 142(1):161–171.
- THURMOND RL, DESAI PJ, DUNFORD PJ et al.: A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. Pharmacol Exp. Ther (2004) 309(1):404–413.
- MELLOR EA, FRANK N, SOLER D et al.: Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc. Nati Acad. Sci. USA (2003) 100(20):11589–11593. Website
Websites
- http://www.durect.com Durect website.
- http://www.emisphere.com Emisphere Technologies website.